Treatment Dose Increase Versus Co‐Medication in Allergic Rhinitis: Systematic Review With Dose–Response Network Meta‐Analysis
Allergy · 2026-11 · 81 (11) · 3797-3812
DOI: 10.1111/all.70372 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Allergy, online erschienen am 01.05.2026. Verfasst von Bernardo Sousa-Pinto und 21 weiteren Autor:innen. Beteiligte Einrichtung: MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences; Faculty of Medicine, University of Porto, Porto, Portugal. Hauptthemen laut MEDLINE: Rhinitis, Allergic, Anti-Allergic Agents, Histamine Antagonists. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ARIA (Allergic Rhinitis and its Impact on Asthma), Montpellier, France, Advanced Research and Invention Agency.
Abstract (Originalsprache)
Background
To achieve adequate symptom control, patients with allergic rhinitis (AR) often need to increase their medication dose or add other treatments (co‐medication). We aimed to perform a systematic review to compare the efficacy and safety of AR medications for increased dose versus co‐medication.
Methods
We searched four bibliographic databases and three trial databases for randomised controlled trials assessing the effect of intranasal and/or oral medications in patients of all ages with seasonal or perennial AR. We performed pairwise meta‐analysis based on direct evidence to compare (i) non‐standard versus standard treatment doses, and (ii) co‐medication strategies versus monotherapy using standard doses. Furthermore, we fitted dose–response network meta‐analysis (NMA) to obtain projected estimates for comparisons involving two times the standard dose of AR medications in monotherapy versus co‐medication with the standard dose of the same medications. We assessed the certainty of evidence using GRADE for NMA.
Results
We included 262 studies. Co‐medication schemes involving oral antihistamines (OAH) + intranasal corticosteroids (INCS) resulted in higher improvements of nasal symptoms and quality of life than doubling the dose of OAH. However, doubling the dose of intranasal medications led to better results than having intranasal medications + OAH. Doubling the dose of INCS was associated with higher efficacy than adding intranasal antihistamines (INAH). No relevant safety differences were found between treatment strategies.
Conclusions
Results favoured (i) doubling the dose of intranasal medications versus adding OAH, and (ii) adding INCS to OAH over doubling the dose of OAH. This study will inform the ARIA‐EAACI 2024–2025 guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences; Faculty of Medicine, University of Porto, Porto, Portugal.
- CINTESIS@RISE-Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal.
- Allergy Unit, Instituto and Hospital CUF, Porto, Portugal.
- Unit of Anatomy, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal.
- Clinical Epidemiology and Research Center (CERC), Humanitas University and Humanitas Research Hospital, Milan, Italy.
- Department of Health Research Methods, Evidence, and Impact & Department of Medicine, Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada.
ORCID-Profile: Bernardo Sousa-Pinto, Rafael José Vieira, Ana Margarida Pereira, Antonio Bognanni, Mattia Giovannini, Ludger Klimek, Holger J Schünemann, Guido Schwarzer, Jean Bousquet
Förderung
- ARIA (Allergic Rhinitis and its Impact on Asthma), Montpellier, France
- Advanced Research and Invention Agency
Zitieren
APA
Sousa-Pinto, B., Vieira, R. J., Gil-Mata, S., Pereira, A. M., Duarte, V. H., Bognanni, A., Marques-Cruz, M., Jemioło, P., Giovannini, M., di Bona, D., Agarwal, A., Dykewicz, M. S., Shamji, M. H., Torres, M. J., Zuberbier, T., Klimek, L., Chu, A. W. L., Schünemann, H. J., Schwarzer, G., …, & ARIA 2024–2025 systematic reviews group (2026). Treatment Dose Increase Versus Co‐Medication in Allergic Rhinitis: Systematic Review With Dose–Response Network Meta‐Analysis. Allergy, 81(11), 3797-3812. https://doi.org/10.1111/all.70372
Vancouver
Sousa-Pinto B, Vieira RJ, Gil-Mata S, Pereira AM, Duarte VH, Bognanni A, et al. Treatment Dose Increase Versus Co‐Medication in Allergic Rhinitis: Systematic Review With Dose–Response Network Meta‐Analysis. Allergy. 2026;81(11):3797-3812. doi:10.1111/all.70372
BibTeX
@article{SousaPinto2026,
author = {Sousa-Pinto, Bernardo and Vieira, Rafael José and Gil-Mata, Sara and Pereira, Ana Margarida and Duarte, Vítor Henrique and Bognanni, Antonio and Marques-Cruz, Manuel and Jemioło, Paweł and Giovannini, Mattia and di Bona, Danilo and Agarwal, Arnav and Dykewicz, Mark S and Shamji, Mohamed H and Torres, Maria Jose and Zuberbier, Torsten and Klimek, Ludger and Chu, Alexandro W L and Schünemann, Holger J and Schwarzer, Guido and Fonseca, João A and Bousquet, Jean and ARIA 2024–2025 systematic reviews group, ARIA 2024–2025 systematic reviews group},
title = {Treatment Dose Increase Versus Co‐Medication in Allergic Rhinitis: Systematic Review With Dose–Response Network Meta‐Analysis},
journal = {Allergy},
year = {2026},
volume = {81},
number = {11},
pages = {3797--3812},
doi = {10.1111/all.70372}
}
EUVIMED